🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against superbug strains of the bacteria, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are on the rise around the world, with estimates suggesting over 82 million instances per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the extremely scarce treatment choices currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in the same week. This treatment, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Global Access

As per findings published in a prominent scientific publication, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in many regions with limited resources.

Medical professionals treating patients have expressed optimism. The availability of a single-dose, oral treatment such as this is seen as a "game-changer" for managing the epidemic. This is viewed as essential to alleviate the strain of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.